Related Experiment Videos
The optimal use of cyclosporin A in autoimmune diseases
1Clinical Research/Immunology, Sandoz Pharma Ltd, Basle, Switzerland.
Insights
Cyclosporin (CsA) can effectively treat autoimmune diseases when used optimally. Careful dosing, monitoring, and short treatment durations minimize risks, ensuring patient safety and therapeutic benefit.
Area of Science:
- Immunology
- Nephrology
- Pharmacology
Background:
- Autoimmune diseases require effective treatments with manageable side effects.
- Cyclosporin (CsA) is an immunosuppressant used for autoimmune conditions.
- Optimizing CsA use is crucial to balance efficacy and safety, especially renal safety.
Purpose of the Study:
- To provide recommendations for the optimal use of cyclosporin (CsA) in autoimmune diseases.
- To define strategies for maximizing the risk/benefit ratio of CsA therapy.
- To prevent irreversible adverse effects, particularly nephrotoxicity.
Main Methods:
- Review of clinical experience with CsA in over 3,000 patients with autoimmune diseases.
- Development of dosing and monitoring guidelines based on empirical data.
- Emphasis on individualized dose titration and continuous patient surveillance.
Main Results:
- Recommends lowest effective initial CsA dose (≤5 mg/kg/day for non-life-threatening conditions).
- Suggests brief treatment (2-4 months) if ineffective; long-term use with lowest effective dose if successful.
- Mandates dose reduction if serum creatinine increases by >30% and continuous monitoring.
Conclusions:
- Optimal CsA use, guided by specific protocols, can lead to effective and safe long-term therapy for selected autoimmune diseases.
- Continuous clinical and biological monitoring (BP, creatinine) is essential for safe CsA prescription.
- Adherence to recommended guidelines minimizes risks and maximizes therapeutic outcomes in CsA-treated patients.
Abstract:
The optimal use of cyclosporin (CsA) in autoimmune diseases aims at achieving the best risk/benefit ratio and ensuring the absence of potentially irreversible adverse effects, particularly with respect to the kidney [corrected]. The experience gained with CsA therapy in more than 3,000 patients with autoimmune diseases is the basis for the current recommendations: the initial dose should be the lowest effective one and not exceed 5 mg/kg/day in non-life-threatening conditions; treatment should be as brief as possible (2-4 months) in cases of inefficacy; once a satisfactory clinical improvement has been achieved, the treatment should be maintained in the long-term using the lowest individually titrated effective dose; the dose of CsA should be decreased when serum creatinine rises by more than 30% above pre-CsA level. Continuous clinical and biological monitoring (especially of blood pressure and serum creatinine) is mandatory as long as CsA is prescribed. When these conditions are fulfilled, CsA may be an effective and safe therapy for selected autoimmune diseases, even in long-term treatment.